Navigation Links
Anthera Presents Data on Varespladib at ATVB Meeting
Date:4/17/2008

SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that Anthera scientists and collaborators have released data from the Varespladib (A-002) clinical and pre-clinical programs at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Annual Conference in Atlanta, Georgia, held on April 16-18, 2008. Anthera has completed Phase II trials in Varespladib for the treatment of coronary heart disease.
Posters include:

-- Effects of a Selective Secretory Phospholipase A2 Inhibitor on

Low-Density Lipoproteins in CHD Patients with Diabetes.

-- The Synergistic Inhibition of Atherogenesis in ApoE-/- Mice Between

Pravastatin and the sPLA2 Inhibitor Varespladib (A-002).

"We are pleased to see the synergistic effect of Varespladib with statins on plaque reduction, composition and stability in a well established model of atherosclerosis," said Joaquim Trias, Ph.D., Senior Vice President of Preclinical Development at Anthera Pharmaceuticals, Inc.

"Along with the Phase II PLASMA data presented at ACC earlier this year, today's announcement gives us added confidence as we move the Varespladib clinical program forward," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "These findings further support our clinical development program as we begin Phase III clinical trials in patients with acute coronary syndromes where inflammation, atherosclerosis and cholesterol levels are highly correlated with outcomes."

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shion
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anthera Pharmaceuticals Forms Scientific Advisory Board
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
4. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
6. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
7. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
8. SGX Presents Preclinical MET Data at AACR
9. ARIUS presents new findings for anti-cancer antibody programs at AACR
10. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
11. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... uBiome, Inc. has announced the ... clinical tests based on its unique microbial assays. ... sparked the era of microbiome-based personalized medicine by ... information about their own bodies using the latest ... uBiome has gathered millions of data points in ...
(Date:4/28/2015)... 2015 Dr. Harton will be responsible ... service operations across the products of Fertility Authority.com, EggBanxx, ... and only FDA-cleared test to use time lapse imaging ... selection during IVF. , Dr. Harton has joined Progyny ... Sciences, including both laboratory management and IVF practice management ...
(Date:4/27/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... year ended December 31, 2014. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... provide the outcome management and investors had hoped ... Therapeutics", said Andrew Rae , President & ...
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
Breaking Biology Technology:uBiome Launches Clinical Laboratory 2Progyny Appoints Gary Harton as Group Senior Vice President, Commercial Development 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... Inc. announced today that it has initiated patient enrollment ... lead product candidate TG-C.  TG-C involves human allogeneic chondrocytes ... regeneration of cartilage in patients suffering from severe osteoarthritis ... placebo-controlled Phase II study will evaluate the safety and ...
... animals grew far more complex than their single-celled ancestors. ... finds that complex organisms, including humans, have accumulated structural ... from microbe to man. The study, published in ... errors into proteins, rather than traditional natural selection, may ...
... 2011 Cellectis bioresearch, a subsidiary of Cellectis ... Wako Pure Chemical Industries as its distributor in ... products and services, including the recently launched TALEN(1) ... distributor of research products in Japan. ...
Cached Biology Technology:TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee 2Errors in protein structure sparked evolution of biological complexity 2Errors in protein structure sparked evolution of biological complexity 3Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan 2
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... 14, 2012) A research team has identified epigenetic ... gene expression, within reprogrammed skin cells. These signatures can ... skin cells or induced pluripotent stem cells (iPSCs), cells ... the expression of the protein is controlled brings us ...
... GABLES, FL (March 14, 2012)--Convincing speeches are central to campaigning ... select our leaders? A newly-published paper in Proceedings of ... and women vote for male and female candidates with lower-pitched ... to be perceived as more competent, stronger, and more trustworthy. ...
... to testicular cells than titanium dioxide nanoparticles, according to ... Health. However, the use of both types may affect ... Commonly used Nanotechnology is increasingly ... potential risks of using engineered nanoparticles need to be ...
Cached Biology News:Epigenetic signatures direct the repair potential of reprogrammed cells 2Are silver nanoparticles harmful? 2
... The Oxidized LDL Competitive ELISA is ... in the sample competes with a fixed amount ... for the binding of the biotin- labeled specific ... 25 l The Oxidized LDL Competitive Enzyme-Linked ...
... For nucleofection of optimized cell lines ... protocol including the nucleofection parameters. Nucleofector ... with the Nucleofector Device., Different cell ... kit. The corresponding efficiencies and viabilities ...
... that is designed for use with HRP conjugated ... a mouse monoclonal coating antibody. • ... to prevent non-specific binding between the coating and ... buffer may be used to stabilize newly conjugated ...
... in solution or in a gel piece, we ... will be digested to produce a mixture of ... are determined by MALDI-TOF, and the amino acid ... MALDI-TOF will be determined by MALDI-TOF/TOF. The masses ...
Biology Products: